Cramer's lightning round: AbbVie needs to make an acquisition—it might just save its stock

This post was originally published on this site

AbbVie Inc.: “AbbVie has to do an acquisition. People are very concerned that they are putting themselves out of business because their biggest drug is coming off patent. It yields 5.5 percent. They ought to just merge with someone. I don’t know why they don’t; the stock has been a straight line down.”

Bank Ozk: “Interesting. I’m going to have to say that I don’t really want exposure to that market, and, frankly, I’ve got to tell you, I need better than a 3 percent yield if I’m going to go into the regionals. The regionals don’t act well.”

Patterson-UTI Energy Inc.: “Patterson-UTI says it all, particularity ‘UTI.’ I don’t want to touch that one. No. Not with me. I suggest you go into Schlumberger.”

Idexx Laboratories Inc.: “I agree with you. Idexx Labs is the humanization of pets.”

3D Systems Corp.: “We got an upgrade today. It looks like business is starting to turn up. But you know what I say? If you want 3D print, then I’m going to send you to [HP Inc.]. HPQ is down too much, [CEO Dion Weisler] is doing a terrific job there.”

Carvana Co.: “We did a very good look at Carvana and we would’ve liked it if they weren’t selling cars. I think the car business is not that good. I come at that because I look at what Union Pacific and what Norfolk Southern say and … I’m not crazy about it.”

Disclosure: Cramer’s charitable trust owns shares of Schlumberger.

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

Add Comment